Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Metastatic Gastric Adenocarcinoma × tipiracil × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 4 Metastatic Gastric Adenocarcinoma 1 Gastric and Gastroesophageal Junction Adenocarcinoma 1

Interventions

trifluridine tipiracil drug combination 1 tipiracil 1 irinotecan sucrosofate 1 Trifluridine 1 Ramucirumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05927857 2026-04-09

Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .

National Health Research Institutes, Taiwan

Phase 1/2 Recruiting

Gastrointestinal

Metastatic Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡